J 2021

Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer

VINKLEROVÁ, Petra, Markéta BEDNAŘÍKOVÁ, Luboš MINÁŘ, Michal FELSINGER, Jitka HAUSNEROVÁ et. al.

Basic information

Original name

Tumor Characteristic Variations between Symptomatic and Asymptomatic Endometrial Cancer

Authors

VINKLEROVÁ, Petra (203 Czech Republic, belonging to the institution), Markéta BEDNAŘÍKOVÁ (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), Michal FELSINGER (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Petra OVESNÁ (203 Czech Republic, belonging to the institution) and Vít WEINBERGER (203 Czech Republic, guarantor, belonging to the institution)

Edition

Healthcare, Basel, MDPI, 2021, 2227-9032

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.160

RIV identification code

RIV/00216224:14110/21:00122021

Organization unit

Faculty of Medicine

UT WoS

000677363300001

Keywords in English

endometrial cancer; tumor markers; ER; PR; p53; L1CAM

Tags

International impact, Reviewed
Změněno: 24/8/2021 10:11, Mgr. Tereza Miškechová

Abstract

V originále

Endometrial cancer is the most common gynecologic malignancy in Europe and usually diagnosed in its initial stage owing to early symptoms of abnormal bleeding. There is no population screening for this disease, although it can sometimes be accidentally diagnosed in asymptomatic patients. Our study aims to determine differences in clinical and tumor characteristics between an asymptomatic and symptomatic group of patients. This unicentric prospective observational study took place in University Hospital Brno between January 2016 and December 2019. A total of 264 patients met inclusion criteria (26% asymptomatic, 74% with reported symptoms). We did not find a statistically significant difference in clinical characteristics (menopausal status, parity, age, BMI, and serum level of CA 125) between groups. According to ultrasound examination, bleeding tumors were larger (19.5 vs. 12.7 mm, p <= 0.001). Definitive histology results indicated more frequent lymphovascular space invasion (p < 0.001), along with deep myometrial (p = 0.001) and cervical (p = 0.002) invasion. There was no difference in advanced stages of the tumor. We did not substantiate statistically significant difference in immunohistochemical profile (estrogen and progesterone receptors, L1 cell adhesion molecule, tumor protein p53), which is relevant for tumor recurrence risk and survival capacity. Our conclusions affirmed that bleeding occurs more often among patients with local tumor invasion into the myometrium and cervical stroma. Final International Federation of Gynecology and Obstetrics (FIGO) stage, histology, and immunohistochemical characteristics do not significantly affect symptom appearance.